Clinical Trial Update: Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial from the Canadian Cancer Trials Group is evaluating trimodality therapy with or without durvalumab for muscle-invasive bladder cancer, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Canadian Cancer Trials Group | Conditions: Bladder Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING